Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA 50010, USA.
J Vet Intern Med. 2010 Mar-Apr;24(2):269-77. doi: 10.1111/j.1939-1676.2009.0447.x.
Although prednisone and metronidazole are commonly used to treat canine inflammatory bowel disease (IBD), no randomized-controlled trials have been performed.
Combination drug therapy with prednisone and metronidazole will be more effective than prednisone alone for treatment of canine IBD. Reduction in disease severity will be accompanied by decreased canine IBD activity index (CIBDAI) scores and serum C-reactive protein (CRP) concentrations.
Fifty-four pet dogs diagnosed with IBD of varying severity.
Dogs were randomized to receive oral prednisone (1 mg/kg; n = 25) or prednisone and metronidazole (10 mg/kg; n = 29) twice daily for 21 days. Clinical (CIBDAI) scores and serum CRP were determined at diagnosis and after 21 days of drug therapy. The primary efficacy measure was remission at 21 days, defined as a 75% or greater reduction in baseline CIBDAI score.
Differences between treatments in the rate of remission (both exceeding 80%) or the magnitude of its change over time were not observed. CRP concentrations in prednisone-treated dogs were increased because of many dogs having active disease. Both treatments reduced CRP in comparison with pretreatment concentrations. An interaction between CIBDAI and CRP was identified in 42 of 54 dogs (78%), whereas 8 of 54 dogs (15%) showed disagreement between these indices.
Prednisone is as effective as combined treatment with prednisone and metronidazole for induction therapy of canine IBD. CRP may be normal or increased in dogs with IBD and may be useful in assessing the response of individual dogs to treatment along with changes in the CIBDAI.
尽管泼尼松和甲硝唑常用于治疗犬炎症性肠病（IBD），但尚未进行随机对照试验。
泼尼松和甲硝唑联合药物治疗将比单独使用泼尼松更有效地治疗犬 IBD。疾病严重程度的降低将伴随着犬 IBD 活动指数（CIBDAI）评分和血清 C-反应蛋白（CRP）浓度的降低。
54 只被诊断患有不同严重程度的 IBD 的宠物犬。
犬被随机分为接受口服泼尼松（1mg/kg；n=25）或泼尼松和甲硝唑（10mg/kg；n=29），每天两次，共 21 天。在诊断时和药物治疗 21 天后，测定临床（CIBDAI）评分和血清 CRP。主要疗效指标为 21 天缓解，定义为 CIBDAI 基线评分降低 75%或以上。
治疗组之间在缓解率（均超过 80%）或其随时间变化的幅度方面没有差异。由于许多犬患有活动性疾病，泼尼松治疗犬的 CRP 浓度增加。与治疗前浓度相比，两种治疗方法均降低了 CRP。在 54 只犬中的 42 只（78%）中发现了 CIBDAI 和 CRP 之间的相互作用，而在 54 只犬中的 8 只（15%）中发现了这些指数之间的不一致。
泼尼松与泼尼松和甲硝唑联合治疗对诱导犬 IBD 的治疗同样有效。CRP 可能在患有 IBD 的犬中正常或增加，并且与 CIBDAI 的变化一起，可用于评估个体犬对治疗的反应。
